Compounds > famotidine
Page last updated: 2024-10-26

famotidine and Cancer of Prostate

famotidine has been researched along with Cancer of Prostate in 2 studies

Famotidine: A competitive histamine H2-receptor antagonist. Its main pharmacodynamic effect is the inhibition of gastric secretion.

Research Excerpts

ExcerptRelevanceReference
"Our results indicate that famotidine could result in a significant reduction in radiation-induced lymphocytopenia and may consequently increase radiotherapy efficacy as well as survival times."9.19Reduction in radiation-induced lymphocytopenia by famotidine in patients undergoing radiotherapy for prostate cancer. ( Aghamiri, SM; Heidari, AH; Mofid, B; Mozdarani, H; Razzaghdoust, A, 2014)
"Our results indicate that famotidine could result in a significant reduction in radiation-induced lymphocytopenia and may consequently increase radiotherapy efficacy as well as survival times."5.19Reduction in radiation-induced lymphocytopenia by famotidine in patients undergoing radiotherapy for prostate cancer. ( Aghamiri, SM; Heidari, AH; Mofid, B; Mozdarani, H; Razzaghdoust, A, 2014)
"Famotidine was well tolerated."2.79Famotidine as a radioprotector for rectal mucosa in prostate cancer patients treated with radiotherapy: phase I/II randomized placebo-controlled trial. ( Mofid, B; Mozdarani, H; Razzaghdoust, A, 2014)

Research

Studies (2)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's2 (100.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Razzaghdoust, A2
Mozdarani, H2
Mofid, B2
Aghamiri, SM1
Heidari, AH1

Trials

2 trials available for famotidine and Cancer of Prostate

ArticleYear
Reduction in radiation-induced lymphocytopenia by famotidine in patients undergoing radiotherapy for prostate cancer.
    The Prostate, 2014, Volume: 74, Issue:1

    Topics: Administration, Oral; Aged; Famotidine; Humans; Lymphopenia; Male; Middle Aged; Prospective Studies;

2014
Famotidine as a radioprotector for rectal mucosa in prostate cancer patients treated with radiotherapy: phase I/II randomized placebo-controlled trial.
    Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al], 2014, Volume: 190, Issue:8

    Topics: Administration, Oral; Aged; Aged, 80 and over; Dose Fractionation, Radiation; Dose-Response Relation

2014